GRI Bio, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from GRI Bio, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 731,800% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than almost all Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 2.6 times its market value (net cash). Higher than 97% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 91% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-181.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 91% of Healthcare companies in United States.
Cash Cushion Ratio
2.6× cashCash, after subtracting all debt, is 2.6 times its market value (net cash).
Higher than 97% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
GRI Bio, Inc. made a loss over the last year. GRI Bio, Inc. owes $0.10 for every $1 it owns. GRI Bio, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossGRI Bio, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.30The share price is 0.30 times GRI Bio, Inc.'s book value per share, lower than 96% of Healthcare companies in United States.
Market cap
$3 MThe total market value of all of GRI Bio, Inc.'s shares at today's price (share price × number of shares), smaller than 96% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$10 MWhat GRI Bio, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.70Net worth divided by the number of shares. The share price of $1.42 is 0.3 times this, which is the P/B above.
Return on equity (ROE)
-142.0%GRI Bio, Inc. lost 142.0% of its shareholders' money over the last year, lower than 79% of Healthcare companies in United States.
Owes vs Owns
0.10×GRI Bio, Inc. owes $0.10 for every $1 it owns (low), lower than 87% of Healthcare companies in United States.
Dividend yield
NoneGRI Bio, Inc. does not currently pay a dividend.
Profit growth
LossGRI Bio, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashGRI Bio, Inc. held $8 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For GRI Bio, Inc.: $3 M ÷ $10 M (30 Jun 2026) = 0.3.
What is GRI Bio, Inc.'s return on equity?
GRI Bio, Inc. lost 142.0% of its shareholders' money over the last year, lower than 79% of Healthcare companies in United States.
How much does GRI Bio, Inc. owe compared with what it owns?
GRI Bio, Inc. owes $0.10 for every $1 it owns (low), lower than 87% of Healthcare companies in United States.
Does GRI Bio, Inc. pay a dividend?
No. GRI Bio, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.